Artemisinin-based combination therapy for ... - The Cochrane Library

Comparison 12. Artesunate plus amodiaquine vs Artesunate plus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
7 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Africa 7 Risk Ratio (M-H, Random, 95% CI) Not estimable
2 Total Failure (P. falciparum) Day
28 PCR adjusted
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Africa 7 1419 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.37, 1.08]
3 Gametocyte carriage 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Gametocyte carriage day 0 3 532 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.60, 1.32]
3.2 Gametocyte carriage day 3 2 363 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.67, 1.25]
3.3 Gametocyte carriage day 7 2 363 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.64, 1.61]
3.4 Gametocyte carriage day
14
3 520 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.32, 3.73]
4 Proportion of participants with
anaemia
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 At baseline 2 452 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.83, 1.00]
4.2 At Day 28 2 429 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.79, 1.14]
5 Serious adverse events (including
deaths)
4 1108 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.14, 7.02]
Comparison 13. Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 East Africa 5 3317 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.51, 1.01]
1.2 West Africa 2 766 Risk Ratio (M-H, Random, 95% CI) 6.57 [0.68, 63.26]
1.3 Other 1 155 Risk Ratio (M-H, Random, 95% CI) 3.12 [1.05, 9.25]
2 Total Failure (P. falciparum) Day
28 PCR adjusted
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 East Africa 3 1515 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.22, 0.89]
2.2 West Africa 2 701 Risk Ratio (M-H, Random, 95% CI) 9.72 [1.19, 79.26]
2.3 Other 1 148 Risk Ratio (M-H, Random, 95% CI) 2.23 [0.58, 8.58]
3 Gametocyte development 2 1354 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.54, 0.82]
4 Gametocyte carriage 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Gametocyte carriage day 0 3 909 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.13, 3.59]
4.2 Gametocyte carriage day 3 1 521 Risk Ratio (M-H, Random, 95% CI) Not estimable
4.3 Gametocyte carriage day 7 3 897 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.02, 2.69]
4.4 Gametocyte carriage day
14
3 894 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.16, 2.02]
5 Anaemia 4 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
119